The federal government is expected to announce, on Tuesday (25), at an event at Planalto Palace, an agreement for large-scale production of the first national vaccine and a single dose against dengue. The goal is to offer 60 million annual doses from 2026.
The immunizer, produced by the Butantan Institute, has been studied since 2009 and is in the final stages of development. The pending is the registration stage, authorized by the National Health Surveillance Agency (Anvisa), which still needs to occur before the vaccine is made available to the population.
Today, there are two dengue vaccines in Brazil, both imported. Due to the low worldwide immunizer production capacity, the Unified Health System (SUS) offers the vaccine only for children between 10 and 14 years – public with greater risk of developing serious symptoms of the disease. The rest of the population can acquire the immunizer in a particular way.
The national production of the aim to expand the public that can be vaccinated by the public network to those with two to 59 years, increasing the general immunization of Brazilians and reducing the cases of long term dengue.
The idea is that vaccination becomes the main means of facing disease in the country. According to the government, the total investment for the action will be R $ 1.26 billion.
In 2024, different regions of Brazil had record records of dengue cases. There were 6,041 deaths, a 400%increase, surpassing the deaths by Covid-19.
According to the Ministry of Health, the significant increase in dengue virus serotype 3 is one of the concerns for 2025. The folder bets on new Aedes Egypt mosquito technologies to prevent last year’s situation from repeating.
Other Ads
This Tuesday, the federal government should also announce three other public-private partnerships (PPP), focused on health promotion. The first concerns the national manufacture of insulin Glargina, with a supply scheduled for the second half of this year.
The second measure is a partnership between the Butantan Institute and Pfizer, which will allow the production of up to 8 million annual doses of the respiratory sintendent virus (VSR) vaccine.
There will also be a partnership announcement to ensure the composition of a strategic stock that makes the production of the H5N8 influenza vaccine more agile.
*Under the supervision of Mayara da Paz
